intravenous tissue plasminogen activator (tPA)

DRUG2 trials

Sponsors

Neuroscience Trials Australia, Melbourne Health

Conditions

Ischemic StrokeStroke, Acute, Stroke Ischemic

Phase 2

Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial

TerminatedNCT01492725

Neuroscience Trials AustraliaIschemic Stroke

Start: 2012-06-30End: 2014-12-31Updated: 2015-04-21

Tenecteplase Versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance

CompletedNCT04071613

Melbourne HealthStroke, Acute, Stroke Ischemic

Start: 2019-06-20End: 2021-11-16Updated: 2021-12-08

Related Papers

Abstract 052: External Validation of the Prediction Model For Delayed Reperfusion in Patients with Incomplete Reperfusion: EXTEND‐PROCEED

Stroke Vascular and Interventional Neurology2023-11-01

Thrombectomy Outcomes With General vs Nongeneral Anesthesia

Neurology2022-10-2614 citations

Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial.

2022-05-0497 citations

Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance (Mobile Stroke Unit—TASTE-A): protocol for a prospective randomised, open-label, blinded endpoint, phase II superiority trial of tenecteplase versus alteplase for ischaemic stroke patients presenting within 4.5 hours of symptom onset to the mobile stroke unit

BMJ Open2022-04-018 citations

Prevalence and Significance of Impaired Microvascular Tissue Reperfusion Despite Macrovascular Angiographic Reperfusion (No-Reflow).

2021-12-14110 citations

Endovascular Thrombectomy for Ischemic Stroke Increases Disability-Free Survival, Quality of Life, and Life Expectancy and Reduces Cost

Frontiers in Neurology2017-12-1466 citations

Endovascular Therapy for Ischemic Stroke with Perfusion-Imaging Selection

New England Journal of Medicine2015-02-115733 citations